Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Mar 23, 2018
Clinical News

Sun's IL-23 psoriasis mab approved by FDA

BioCentury | Mar 21, 2018
Company News

Sun's IL-23 mAb gets FDA approval for psoriasis

BioCentury | Feb 28, 2018
Distillery Therapeutics

Cancer

BioCentury | Jul 13, 2017
Company News

Almirall lowers guidance

BioCentury | Jul 10, 2017
Financial News

Almirall sags after lowering guidance

BioCentury | May 24, 2017
Clinical News

FDA reviewing Sun's psoriasis candidate

BioCentury | Mar 31, 2017
Clinical News

Tildrakizumab regulatory update

BioCentury | Oct 10, 2016
Clinical News

Tildrakizumab: Additional Phase III data

Items per page:
1 - 10 of 22